hide message

Welcome to the Resource Centre

We make it our mission to work with advocates in civil society, business and government to address inequalities of power, seek remedy for abuse, and ensure protection of people and planet.

Both companies and impacted communities thank us for the resources and support we provide.

This is only possible because of your support. Please make a donation today.

Thank you,
Phil Bloomer, Executive Director

Donate now hide message

You are being redirected to the story the piece of content is found in so you can read it in context. Please click the following link if you are not automatically redirected within a couple seconds:
en/glaxo-novo-merck-lead-on-access-to-medicines-according-to-new-ranking#c31543

European firms beat U.S. on drug access for poor

Author: Ben Hirschler, Reuters, Published on: 16 June 2008

European drugmakers are better than their U.S. counterparts in ensuring medicines reach people in poor countries, with Britain's GlaxoSmithKline Plc leading the field, according to an analysis on Monday. The ranking -- the first of its kind -- was produced by the Netherlands-based Access to Medicine Foundation and is backed by 12 fund managers, who together manage $1.2 trillion in assets. The ranking is based on eight main criteria, including companies' policies on increasing access, patenting, research into neglected diseases and the use of fair pricing systems...
The full ranking is as follows:
GlaxoSmithKline PLC
Novo Nordisk [part of Novo Group]
Merck & Company Inc
Novartis AG
Sanofi-Aventis
AstraZenica PLC
Roche Holdings Limited
Johnson & Johnson
Bayer Schering Pharma AG [part of Bayer]
Eli Lilly & Company
Bristol-Myers Squibb Comp
Abbott Laboratories Ltd
Merck Kgaa AG
Cipla Limited
Gilead Sciences Inc
Ranbaxy Laboratories Ltd
Pfizer Inc
Wyeth
Teva Pharmaceutical...
Schering-Plough Corp

Read the full post here

Related companies: Abbott Laboratories AstraZeneca Bayer Bristol-Myers Squibb Cipla Eli Lilly Gilead Sciences GlaxoSmithKline Johnson & Johnson Merck Novartis Novo Group Novo Nordisk (part of Novo Group) Pfizer Ranbaxy Laboratories Roche Sanofi Schering-Plough Teva Pharmaceutical Wyeth (part of Pfizer)